Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK. Zhu AX, et al. Among authors: rosmorduc o. J Clin Oncol. 2015 Feb 20;33(6):559-66. doi: 10.1200/JCO.2013.53.7746. Epub 2014 Dec 29. J Clin Oncol. 2015. PMID: 25547503 Free article. Clinical Trial.
[Therapeutic advances in hepatocellular carcinoma].
Poupon R, Fartoux L, Rosmorduc O. Poupon R, et al. Among authors: rosmorduc o. Bull Acad Natl Med. 2008 Jan;192(1):23-31; discussion 31-2. Bull Acad Natl Med. 2008. PMID: 18663979 Review. French.
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.
André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W. André T, et al. Among authors: rosmorduc o. Br J Cancer. 2008 Sep 16;99(6):862-7. doi: 10.1038/sj.bjc.6604628. Br J Cancer. 2008. PMID: 19238628 Free PMC article. Clinical Trial.
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O, Chevreau C, Dielenseger P, Ederhy S, Goldwasser F, Grange JD, Mortier L, Neidhardt-Berard ME, Robert C, Scotté F, Seitz JF. Rosmorduc O, et al. Gastroenterol Clin Biol. 2010 Mar;34(3):161-7. doi: 10.1016/j.gcb.2009.12.004. Epub 2010 Feb 23. Gastroenterol Clin Biol. 2010. PMID: 20181452 Free article. Review. French.
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, Peña CE. Zhu AX, et al. Among authors: rosmorduc o. Clin Cancer Res. 2016 Oct 1;22(19):4870-4879. doi: 10.1158/1078-0432.CCR-15-2883. Epub 2016 May 24. Clin Cancer Res. 2016. PMID: 27220960 Clinical Trial.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Bruix J, et al. Among authors: rosmorduc o. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Lancet. 2017. PMID: 27932229 Clinical Trial.
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Finn RS, et al. Among authors: rosmorduc o. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26. J Hepatol. 2018. PMID: 29704513 Clinical Trial.
117 results